Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.69)
# 2,018
Out of 5,182 analysts
53
Total ratings
40.43%
Success rate
7.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Initiates: Overweight | n/a | $6.99 | - | 1 | Apr 27, 2026 | |
| MANE Veradermics | Initiates: Overweight | n/a | $101.00 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $24.50 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $513.72 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.83 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $13.71 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $42.21 | +53.99% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $9.77 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $44.12 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $4.41 | - | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.49 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.39 | +127.79% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.73 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $33.85 | -29.10% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.61 | +17,141.38% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $2.08 | +573.08% | 1 | Mar 3, 2021 |
Shattuck Labs
Apr 27, 2026
Initiates: Overweight
Price Target: n/a
Current: $6.99
Upside: -
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $101.00
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.50
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $513.72
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $13.71
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $42.21
Upside: +53.99%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.77
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $44.12
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.41
Upside: -
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.49
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.39
Upside: +127.79%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.73
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $33.85
Upside: -29.10%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.61
Upside: +17,141.38%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $2.08
Upside: +573.08%